1100P Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis

Authors:
  • ISI.V. Samoylenko
    I.V. Samoylenko
  • LDL. Demidov
    L. Demidov
  • SDS. Dziamidava
    S. Dziamidava
  • AZA. Zimina
    A. Zimina
  • VKV. Kozlov
    V. Kozlov
  • SOS. Odintsova
    S. Odintsova
  • ISI. Shumskaya
    I. Shumskaya
  • NFN. Fadeeva
    N. Fadeeva
  • IUI. Utyashev
    I. Utyashev
  • KPK.D. Penkov
    K.D. Penkov
  • DSD. Stroyakovskiy
    D. Stroyakovskiy
  • DKD. Kirtbaya
    D. Kirtbaya

Abstract
No abstract available